TAGline 2013

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

Rising to the Domestic Challenge
Funding cuts and shifting budgetary priorities threaten tuberculosis gains
U.S. TB Control: From Confidence to Crisis
Bold strategies are required to remedy frequent stock-outs and supply interruptions
An Obligatory Overhaul to Address Domestic TB Drug Shortages
President Obama orders multiagency cooperation to achieve National HIV/AIDS Strategy goals, but without required funding commitment
A Commitment to the HIV Continuum of Care
Getting more HIV-positive people linked to and retained in care requires innovation and research
Engagement in Care: A Final Frontier of HIV Medicine
A coalition of community groups push to end AIDS at the epicenter of the U.S. epidemic
Toward a Plan to End AIDS in New York State
A series of discussions to reenvision the state’s HIV/AIDS response to encourage the government to develop a New York State plan to end AIDS have begun.
HIV Prevention Is the Surest Way to Fight AIDS
ACT UP/NY demands Department of Health accountability at the epicenter of the U.S. epidemic and commits to reinvigorate the national prevention agenda
TAG’s Commitment to HIV Prevention
Though the number of new HIV infections in the United States is down from its peak in the 1980s, incidence has refused to budge below its decade-long average.
Emerging Regulatory Issues in HIV Cure Research
The science of discovery comes with ethical challenges in human clinical trials

Advancing Research, Securing Access
Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis.
Ryan White at a Crossroads
Preparing to defend and reshape a still-critical program
The "G" Word
Gilead’s greed gives rise to a slew of advocacy priorities
TB Drugs for Children
Poor treatment options spur innovative research strategies
Razing the House of Cards
The discovery of HAART and the push for evidence-based HIV treatment
Preparing for Generics
The push for affordable HIV treatment doesn’t end with patent expirations
Undetectable Is Not Always Enough
Immunologic nonresponders face increased risk of illness, but lack therapeutic options
Sanofi’s Double-Edged Sword
Rifapentine’s manufacturer helps to advance TB research while stalling access
A Necessary Transformation
Simultaneous, not sequential, evaluations of novel drug regimens needed to speed TB treatment research
Help Paying for HIV and Hepatitis Treatment
Health insurance co-payment (co-pay) programs and patient drug assistance programs (PAPs) are critical services for thousands of U.S. residents with HIV and/or viral hepatitis who face out-of-pocket expenses associated with their treatment.

TAGLINE ARCHIVE